More Entropy Neurodynamics Limited news
Entropy Neurodynamics LimitedASX: ENP

Plexaris product engineered to deliver anti-cancer drug

May 24, 2020 at 11:23 PM EDT · Issued by Entropy Neurodynamics Limited

Filed with ASX · May 24, 2020 at 11:23 PM EDT · 4 pages · English

On 6ix: 6ix.com/news/plexaris-product-engineered-to-deliver-anti-cancer-drug

Entropy Neurodynamics Limited on 6ix

Earlier from Entropy Neurodynamics

  • March Quarterly Report and Appendix 4CApr 24, 2020
  • PLEXOVAL I study disrupted by the Covid-19 responseMar 31, 2020
  • Appendix 4D and Interim Financial ReportFeb 20, 2020
  • Cevaris testing shows positive results in bladder controlFeb 19, 2020
  • Cevaris testing shows positive results in models of EDFeb 18, 2020

Later from Entropy Neurodynamics

  • Shareholder UpdateMay 27, 2020
  • Added IP empowers Exopharms engineered exosome pipelineJun 11, 2020
  • June Quarterly Report and Appendix 4CJul 30, 2020
  • Appendix 4E and Annual Financial Report FY 2020Aug 26, 2020
  • Exopharm raises $10m in well supported PlacementAug 26, 2020
All Entropy Neurodynamics news releases↗

Follow Entropy Neurodynamics into a list and get an email when it puts out news.

Follow Entropy Neurodynamics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer